Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JYEST cell injection
- Development stage
- Phase 1
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
JYEST cell injection is a donor-derived Epstein-Barr virus (EBV)-specific T-cell therapy developed by the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences. It consists of T cells harvested from a donor and expanded ex vivo to specifically target EBV antigens. The therapy is designed to provide adoptive immunotherapy for the prevention and treatment of EBV infection and EBV-associated post-transplant lymphoproliferative disorder (PTLD) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). By restoring EBV-specific immunity in the immunocompromised recipient, these T cells aim to control viral replication and prevent clinical disease.
- Other names
- Donor-derived EBV-specific T cellsEBV-specific T cellsJYEST Cell Injection Infusion
02
Targets
EBNA1 (Epstein-Barr virus latency proteins)
Beyond the preview
Go deeper on JYEST cell injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JYEST cell injection.